Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Exact Sciences Corporation Banner

Exact Sciences Corporation

EXAS Stock Analysis

Page title

Section title

About Exact Sciences Corporation

Medical - Diagnostics & Research
Healthcare

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services...

Exact Sciences Corporation Key Metrics

Market Cap
$13B
52 Weeks Low
$40.62
52 Weeks High
$79.62
P/B
4.13x
P/E
-75.27x
P/S
5.06x

Upcoming Events

    EXAS Analyst Forecasts

    ‌
    ‌

    EXAS Financials

    EXAS Income Statement Key Metrics

    • Revenue(TTM)2.61 B
    • Gross Profit(TTM)1.89 B
    • EBITDA(TTM)-2.37 M
    • Net Income(TTM)-175.01 M
    • EPS Diluted(TTM)-0.9515

    Decode EXAS's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    EXAS earnings and revenue history

    EXAS Return on Equity

    See how efficiently EXAS generates profit for it's shareholders.

    -6.49%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    EXAS's Return on Equity has shown poor growth over the past 10 years, increasing by only -15.41%.

    EXAS Revenue Growth

    See how EXAS has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    EXAS's revenue has grown significantly over the past 10 years, increasing by over 106.21%.